PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange, announced today that cooperation agreements were signed with two worldwide leading research laboratories to promote the Company’s second drug pipeline, CF102. This cooperation will facilitate joint research to investigate the effect of CF102 on hepatitis C virus (HCV) replication in hepatocytes and elucidate the molecular mechanisms underlying the antiviral activity of CF102. One agreement was signed with Prof. Turkaspa, a world renowned expert in the research and treatment of liver diseases from the Rabin Medical Center in Israel; the second agreement was signed with Prof. Khalili, head of the Center for Neurovirology and Cancer Biology at Philadelphia Temple University and editor of scientific magazines in these fields.
